Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
HCP5
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Upstream regulatory factors
Not available
Downstream target
PTEN
Cancer name
Triple-Negative Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
We found that downregulation of HCP5 contributed to DDP resistance in TNBC, while overexpression of HCP5 reversed the resistance via upregulating PTEN level. Therefore, DDP combined with overexpression of HCP5 might be considered as a therapeutic approach for the treatment of DDP-resistant TNBC.
Tissue resource
human triple-negative breast cancer cell lines MDA-MB-231
human triple-negative breast cancer cell lines MDA-MB-157
human triple-negative breast cancer cell lines MDA-MB-468
human triple-negative breast cancer cell lines HCC1806
human embryonic kidney cell lines HEK-293T
Experiment
qRT-PCR,Western blot,microarray assay
Institute
American Type Culture Collection
Country
USA
Continent
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.